RESUMEN
In this study, we have developed a facile method for preparation of highly fluorescent Au nanoclusters (AuNCs) using 11-mercaptoundecanoic acid (MUA) as both the reducing and stabilizing agent. The as-prepared MUA functionalized AuNCs (MUA-AuNCs) have good water solubility, excellent photostability, and strong fluorescence emission at 610 nm with a quantum yield of 7.28% in water. The fluorescence of MUA-AuNCs was first quenched by copper ions through electron transfer, subsequently caused obvious restoration by competitive effect after adding penicillamine, making it a potential fluorescent sensor for penicillamine with a detection limit of 0.08 µM. Furthermore, the newly designed fluorescence "on-off-on" assay was explored for the measurement of penicillamine in complex real water and urine samples with satisfactory results.
Asunto(s)
Antirreumáticos/análisis , Ácidos Grasos/química , Colorantes Fluorescentes/química , Oro/química , Nanopartículas del Metal/química , Penicilamina/análisis , Compuestos de Sulfhidrilo/química , Contaminantes Químicos del Agua/análisis , Antídotos/análisis , Antídotos/farmacocinética , Antirreumáticos/orina , Cobre/química , Excipientes/química , Humanos , Lagos/análisis , Límite de Detección , Nanopartículas del Metal/ultraestructura , Penicilamina/orina , Sustancias Reductoras/química , Espectrometría de Fluorescencia/métodos , Contaminantes Químicos del Agua/orinaRESUMEN
BACKGROUND: Chloroquine and hydroxychloroquine are medical drugs used to treat the chemoprophylaxis of malaria and a second-line anti-inflammatory drug. METHODS: We performed a study of cross-reactivity of chloroquine and hydroxychloroquine in the DRI Amphetamine Assay inspired by a case report of a self-ingestion of chloroquine after a family dispute, that involved the following: (1) an in vitro study with control samples of healthy subjects, (2) an in vivo study with samples of patients with rheumatoid arthritis, and (3) an evaluation of the cross-reactivity of chloroquine and hydroxychloroquine in 3 additional immunoassays. RESULTS: In the case report, the Amphetamine DRI assay resulted positive both at 1000 ng/mL cutoff (1507 and 1137 ng/mL) and at 500 ng/mL cutoff (1178 and 642 ng/mL). Chloroquine urine levels were 103,900 and 100,900 ng/mL at 5 and 9 hours after ingestion. The results with control samples showed a positive cross-reactivity of chloroquine in the DRI Amphetamine Assay (approximately 0.74% and 0.89% at cutoff of 1000 and 500 ng/mL, respectively). Hydroxychloroquine did not cross-react with the DRI Amphetamine Assay up to 1,000,000 ng/mL. In patients treated with chloroquine or hydroxychloroquine, DRI Amphetamine did not produce false-positive results. The comparative assay study showed a positive cross-reactivity of chloroquine in the Emit II Plus Amphetamines Assay with control samples. CONCLUSIONS: Chloroquine can cause false-positive results in the DRI Amphetamine Assay when it is present at high concentrations. Hydroxychloroquine did not produce false-positive results neither in the DRI Amphetamine Assay nor in the others immunoassays evaluated.
Asunto(s)
Anfetamina/orina , Cloroquina/orina , Hidroxicloroquina/orina , Adolescente , Anfetamina/uso terapéutico , Antirreumáticos/orina , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/orina , Cloroquina/uso terapéutico , Reacciones Cruzadas/fisiología , Femenino , Humanos , Hidroxicloroquina/uso terapéutico , Inmunoensayo/métodos , Detección de Abuso de Sustancias/métodosRESUMEN
The new oral 200-mg rifamycin SV MMX modified-release tablets, designed to deliver rifamycin SV directly into the colonic lumen, offer considerable advantages over the existing immediate-release antidiarrheic formulations. In two pharmacokinetics studies of healthy volunteers, the absorption, urinary excretion, and fecal elimination of rifamycin SV after single- and multiple-dose regimens of the new formulation were investigated. Concentrations in plasma of >2 ng/ml were infrequently and randomly quantifiable after single and multiple oral doses. The systemic exposure to rifamycin SV after single and multiple oral doses of MMX tablets under fasting and fed conditions or following a four-times-a-day (q.i.d.) or a twice-a-day (b.i.d.) regimen could be considered negligible. With both oral regimens, the drug was confirmed to be very poorly absorbable systemically. The amount of systemically absorbed antibiotic excreted by the renal route is far lower than 0.01% of the administered dose after both the single- and multiple-dose regimens. The absolute bioavailability, calculated as the mean percent ratio between total urinary excretion amounts (ΣXu) after a single intravenous injection and after a single oral dose under fasting conditions, was 0.0410±0.0617. The total elimination of the unchanged rifamycin SV with feces was 87% of the administered oral dose. No significant effect of rifamycin SV on vital signs, electrocardiograms, or laboratory parameters was observed.
Asunto(s)
Rifamicinas/administración & dosificación , Rifamicinas/farmacocinética , Comprimidos/administración & dosificación , Comprimidos/farmacocinética , Adulto , Anciano , Antirreumáticos/administración & dosificación , Antirreumáticos/sangre , Antirreumáticos/farmacocinética , Antirreumáticos/orina , Femenino , Humanos , Masculino , Persona de Mediana Edad , Rifamicinas/sangre , Rifamicinas/orinaRESUMEN
A uniquely developed high performance thin-layer chromatographic (HPTLC) method coupled with UV detection was applied using quality by design approach (QbD) for simultaneous determination of methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ) in serum and urine samples of rheumatoid arthritis patients. MTX, SSZ with HCQ are the most common disease-modifying antirheumatic drugs (DMARDs) combination used for the treatment of rheumatoid arthritis. This ternary mixture with montelukast (MK) added as internal standard, were separated by using a mixture of ethyl acetate: methanol: 25% ammonia, (8: 2: 3, v/v/v) as a mobile phase system. The separation was achieved on HPTLC precoated silica gel plate 60 F254 and the detection was carried out at 306â¯nm for MTX and at 340â¯nm for both SSZ and HCQ. The design was planned to obtain the most optimum retardation factors (Rf) with best resolution. The Rf values for MTX, SSZ, MK and HCQ were of 0.31⯱â¯0.03, 0.62⯱â¯0.02, 0.71⯱â¯0.02 and 0.83⯱â¯0.03; respectively. The interactive response optimizer achieved the most favorable conditions with acceptable composite desirability of 0.9703. Linear relationship with good correlation coefficients (râ¯=â¯0.9990-0.9994) were also obtained with detection and quantification limits of 13.94-260.64 and 46.84-1810.01(ng/ml); respectively. The suggested method was established in accordance with the guidelines of Food and Drug Administration (FDA). The established QbD-HPTLC method achieved simple, sensitive and selective quantification of the studied drugs in serum and urine samples in the presence of their metabolites with no interferences. This method can be extended effectively for therapeutic drug monitoring and pharmacokinetics studies of these drugs.
Asunto(s)
Antirreumáticos/sangre , Antirreumáticos/orina , Artritis Reumatoide/sangre , Artritis Reumatoide/orina , Cromatografía en Capa Delgada/métodos , Adulto , Femenino , Humanos , Hidroxicloroquina/sangre , Hidroxicloroquina/orina , Masculino , Metotrexato/sangre , Metotrexato/orina , Persona de Mediana Edad , Sulfasalazina/sangre , Sulfasalazina/orinaRESUMEN
BACKGROUND: LBPT is a novel platelet-activating factor (PAF) receptor antagonist that is developed for the treatment of rheumatoid arthritis. The purpose of this first-in-human study was to evaluate the tolerability and safety of LBPT, to investigate the pharmacokinetics of LBPT and its primary metabolites, as well as to assess the food effect on the pharmacokinetics in healthy Chinese subjects. MATERIALS AND METHODS: LBPT was evaluated in 2 clinical studies. The first study was a double blind, placebo-controlled and ascending dose study. Eighty-five healthy Chinese subjects received oral dose of 2, 4, 6, 8, 15, 25, 50, 75, 100, 125, 150, 225, 300, 400 or 500mg of LBPT or placebo. The pharmacokinetics of LBPT and its primary metabolites were investigated in the last 4 dose cohorts. The tolerability was evaluated by monitoring adverse events (AEs), physical examinations, 12-lead electrocardiograms (ECG) and laboratory tests. The second study was an open-label, 2-period cross-over study with a washout interval of 3days. Twelve subjects received 300mg of LBPT after an overnight fasting or a high-fat breakfast. The pharmacokinetics of LBPT in subjects under fasted and fed conditions were compared. RESULTS: LBPT was well tolerated up to 500mg-dose and there were no serious AEs in the study. The incidence and severity of AEs were closely related to dose. Following single oral administration of 225, 300, 400 and 500mg of LBPT, plasma Cmax was reached at 0.5h and the mean t1/2 was 0.6-1.6h. Plasma exposure increased with dose escalation but proportionality was not observed. LBPT was eliminated in forms of metabolites and 20-40% of the given dose was recovered in urine. Compared with the subjects under fasting conditions, AUC and Cmax were lower and tmax was delayed in the fed subjects. CONCLUSION: LBPT was well tolerated in healthy subjects with a pattern of dose-related AEs. The pharmacokinetics was non-linear and was impacted by food intake.
Asunto(s)
Antirreumáticos/farmacocinética , Interacciones Alimento-Droga , Piperidinas/farmacocinética , Administración Oral , Adulto , Antirreumáticos/efectos adversos , Antirreumáticos/sangre , Antirreumáticos/orina , Área Bajo la Curva , Pueblo Asiatico , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Voluntarios Sanos , Humanos , Masculino , Piperidinas/efectos adversos , Piperidinas/sangre , Piperidinas/orina , Glicoproteínas de Membrana Plaquetaria/antagonistas & inhibidores , Receptores Acoplados a Proteínas G/antagonistas & inhibidores , Adulto JovenRESUMEN
The interaction of D-penicillamine (PA) with copper at the carbon paste electrode (CPE) in the presence of cupric ions (Cu(2+)) was used for the determination of PA at very low potential (0.1 V vs. Ag/AgCl) without applying of any modifier. The electrochemical response of copper is changed considerably in the presence of negligible amount of PA. In this report some important parameters, such as pH effect, Cu(2+) concentration and scan rate are studied, which the selected conditions were acetate buffer (pH=6) and 1 mM Cu(2+). The linear range for PA was from 1.0×10(-6) to 1.0×10(-4) M with an experimental detection limit of 1.0×10(-7) M. The relative standard deviation for 6 measurements was 3.8%. The interfering effects of some important inorganic ions were investigated, which there was no significant effect on the PA measurements. Also three organic interferences including ascorbic acid (AA), uric acid (UA) and l-cysteine (Cys) were examined, which the effect of AA was not notable, the interference of UA was moderate and for Cys was significant, but moderate at the levels which fined in the urine samples. This method was applied successfully for the determination of PA in urine sample.
Asunto(s)
Antirreumáticos/orina , Carbono/química , Técnicas Electroquímicas/instrumentación , Penicilamina/orina , Cationes Bivalentes/química , Cobre/química , Electrodos , Humanos , Límite de DetecciónRESUMEN
AIM: To carry out a pilot study to investigate the effect of short-term oral probiotic administration on the metabolism of sulfasalazine (SSZ) in patients with rheumatoid arthritis (RA) stabilized on SSZ. METHODS: Twelve subjects with RA taking stable doses of SSZ for a minimum of 3 months prior to the study, received a probiotic preparation contained three strains of bacteria (1.8 x 10(9) CFU/day) twice daily for 1 week. Single point blood and 12-h urine samples were taken before and after probiotic treatment and 3 weeks following discontinuation of probiotics, for determination of SSZ and its metabolites. The presence of the probiotic bacteria in the feces of patients was investigated by denaturing gradient gel electrophoresis (DGGE). RESULTS: Adverse events recorded were three instances of gastrointestinal disturbance and one flare of RA. Plasma and urinary levels of SSZ and its metabolites showed no statistically significant changes after probiotic administration and the incidence of gastrointestinal disturbance did not appear to be ascribed to higher sulfapyridine plasma levels. Probiotic-specific DGGE bands were detected in the feces of some patients after the treatment period. CONCLUSIONS: Short-term treatment of RA patients with a multi-strain probiotic did not significantly influence SSZ metabolism as has been demonstrated in animal models.
Asunto(s)
Antirreumáticos/metabolismo , Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Probióticos/administración & dosificación , Sulfasalazina/metabolismo , Sulfasalazina/uso terapéutico , Administración Oral , Adulto , Anciano , Antirreumáticos/efectos adversos , Antirreumáticos/sangre , Antirreumáticos/orina , Artritis Reumatoide/microbiología , Bifidobacterium/crecimiento & desarrollo , Bifidobacterium/metabolismo , Biotransformación , Interacciones Farmacológicas , Heces/microbiología , Femenino , Humanos , Lactobacillus acidophilus/crecimiento & desarrollo , Lactobacillus acidophilus/metabolismo , Masculino , Persona de Mediana Edad , Proyectos Piloto , Probióticos/efectos adversos , Streptococcus/crecimiento & desarrollo , Streptococcus/metabolismo , Sulfapiridina/sangre , Sulfapiridina/orina , Sulfasalazina/efectos adversos , Sulfasalazina/sangre , Sulfasalazina/orinaRESUMEN
Liquid-phase microextraction based on polypropylene hollow fibers and CE were applied for the chiral determination of hydroxychloroquine (HCQ) and its metabolites (desethylchloroquine, DCQ; desethylhydroxychloroquine, DHCQ; bisdesethylchloroquine, BDCQ) in human urine. The analytes were extracted from 3 mL of urine spiked with the internal standard (metoprolol) and alkalinized with 250 muL of 2 M NaOH. The analytes were extracted into 1-octanol impregnated in the pores of the hollow fiber, and into an acid acceptor solution inside the hollow fiber. The electrophoretic separations were carried out in 100 mmol/L Tris buffer (pH adjusted to 9.0 with phosphoric acid) containing 1% w/v S-beta-CD and 30 mg/mL HP-beta-CD with a constant voltage of +18 kV. The method was linear over the concentration range of 10-1000 ng/mL for each HCQ stereoisomer and 21-333 ng/mL for each metabolite stereoisomer. Within-day and between-day assay precision and accuracy for the analytes were studied at three concentration levels for each stereoisomer and were lower than 15%. The developed method was applied for the determination of the cumulative urinary excretion of HCQ, DCQ, and DHCQ after oral administration of rac-HCQ to a health volunteer. The results obtained are in agreement with previous literature data.
Asunto(s)
Antirreumáticos/química , Hidroxicloroquina/química , Antirreumáticos/farmacocinética , Antirreumáticos/orina , Electroforesis Capilar , Humanos , Hidroxicloroquina/farmacocinética , Hidroxicloroquina/orina , IsomerismoRESUMEN
We have developed esonarimod, (+/-)-2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid, as a new antirheumatic drug. Now we describe herein the preparation of the enantiomers of (+/-)-deacetylesonarimod, the pharmaceutically active metabolites of esonarimod, and comparison of their antirheumatic activities. No significant difference has been observed between the two enantiomers. In a pre-clinical study of esonarimod, other metabolites were detected in rat blood or urine. We also synthesized these compounds as authentic samples to analyze the human metabolites in clinical studies of esonarimod.
Asunto(s)
Antirreumáticos/síntesis química , Antirreumáticos/metabolismo , Animales , Antirreumáticos/sangre , Antirreumáticos/orina , Humanos , Cetonas , Fenilpropionatos/síntesis química , Fenilpropionatos/metabolismo , Ratas , Estereoisomerismo , Relación Estructura-Actividad , SulfurosRESUMEN
An oligomeric 1:1 gold(I) complex of the chromophoric thiol 5-mercapto (2-nitrobenzoate) has been synthesized and applied as a spectrophotometric probe for the thiol-exchange reactions of structurally-analogous 1:1 gold(I)-thiolate drugs. For low-molecular-mass thiols, results were consistent with the initial formation of a monomeric mixed-ligand bis-thiolato gold(I) complex followed by further ligand substitution by excess thiol to produce 5-mercapto (2-nitrobenzoate) and a monomeric bis-thiolato gold(I) complex. For human serum albumin, however, the spectrophotometric changes were only consistent with the binding of gold(I) to its single cysteine residue (Cys-34) with the retention of the 5-mercapto (2-nitrobenzoate) ligand on gold(I).
Asunto(s)
Antirreumáticos/metabolismo , Oro , Nitrobenzoatos , Antirreumáticos/sangre , Antirreumáticos/orina , Humanos , Indicadores y Reactivos , Cinética , Ligandos , Albúmina Sérica/análisis , Espectrofotometría Ultravioleta , Compuestos de SulfhidriloRESUMEN
The biotransformation of esonarimod (KE-298) [(+/-)-2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid], a new antirheumatic drug, was investigated in rats. Urinary and biliary excretions within 24 h after oral administration of 5 mg/kg [(14)C]esonarimod accounted for 89 and 10% of the dose, respectively. Initial metabolite analysis by liquid chromatography/electrospray ionization tandem mass spectrometry with negative ion mode, in which a mobile phase of 20 mM ammonium acetate (pH 4.6)/methanol with gradient-elution mode was used, failed to obtain any structural information on most of the metabolites due to poor sensitivity. To overcome this problem, postcolumn addition of 2-(2-methoxyethoxy)ethanol, a powerful signal-enhancing modifier, to the mobile phase was used, allowing pronounced signal enhancement and structural elucidation of urinary and biliary metabolites. The results of metabolite analysis suggested that esonarimod is predominantly biotransformed to a pharmacologically active metabolite, thiol-containing deacetyl-esonarimod (M-I), and subsequently undergoes extensive metabolism, mainly S-methylation followed by the combination of S-oxidation and oxidative conversion of the aromatic methyl group. No disulfide metabolites, such as M-I-cysteine mixed disulfide and M-I-dimer, were found in the excreta. This finding is probably evidence supporting the notion that the reactivity of the thiol moiety of M-I with macromolecules in vivo is extremely lower than that of common thiol-containing drugs.
Asunto(s)
Antirreumáticos/farmacocinética , Bilis/metabolismo , Cromatografía Líquida de Alta Presión/métodos , Etanol/análogos & derivados , Etanol/química , Espectrometría de Masa por Ionización de Electrospray/métodos , Animales , Antirreumáticos/orina , Masculino , Fenilbutiratos , RatasRESUMEN
1. Metabolites of the cyclic bisphosphonate ester, 4-[2,2'-bis-(5,5- dimethyl-1,3,2-dioxaphosphorinan-2-yl)] butanoyl-3-fluoro-benzene (PNU-91638) in bile or urine of the male Sprague-Dawley rat were characterized by mass spectrometry. The chronically bile duct/duodenal-cannulated male rats received a single oral dose of 100 mg/kg [13C] [14C]PNU-91638. Bile and urine samples were analysed for radioactivity and profiled by hplc with radiometric and UV detection. 2. The 0-28-h bile and urine accounted for 46.0 and 19.7% of dose respectively. The structures of radioactive peaks were investigated by ionspray and liquid secondary ion mass spectrometry (LSIMS) and LSIMS/MS analysis. 3. Major metabolites in urine included two regioisomeric phenol glucuronides, a gem methyl hydroxylated metabolite of the bisphosphonate heterocycle, a phenol metabolite, parent drug and a benzylic alcohol metabolite. Additional metabolites in bile included an unstable phenol/glutathione adduct (from a putative epoxide intermediate) with several minor isobaric regioisomers, and a carboxylic acid derived from the gem methyl hydroxylated bisphosphonate ring. 4. The structures proposed have not been confirmed by nmr due to discontinuation of the development of PNU-91638.
Asunto(s)
Antirreumáticos/metabolismo , Difosfonatos/metabolismo , Animales , Antirreumáticos/farmacocinética , Antirreumáticos/orina , Bilis/metabolismo , Sistema Biliar/metabolismo , Radioisótopos de Carbono , Cromatografía Liquida , Difosfonatos/farmacocinética , Difosfonatos/orina , Estabilidad de Medicamentos , Masculino , Espectrometría de Masas , Ratas , Ratas Sprague-DawleyRESUMEN
1. Stereoselectivity in the disposition of hydroxychloroquine was investigated in 23 healthy males following a single oral dose of 200 mg racemic HCQ (rac-HCQ) sulphate. Total concentrations (R+S) and R/S ratios of HCQ and its metabolites were measured by stereoselective h.p.l.c. 2. HCQ was detected in whole blood and urine, up to 91 and 85 days after dosing, respectively. Metabolites could not be detected in whole blood while in urine detectable concentrations were still present after 85 days. The blood concentrations of HCQ enantiomers were measurable until 168 h post-dose. 3. R(-)-HCQ accounted for 62 +/- 3% (mean +/- s.d.) of the AUC of rac-HCQ AUC. The elimination half-life of S(+)-HCQ (457 +/- 122 h) was significantly shorter than that of R(-)-HCQ (526 +/- 140 h), partly due to its faster urinary excretion and hepatic metabolism. Its renal clearance was twice that of R(-)-HCQ (4.61 +/- 4.01 vs 1.79 +/- 1.30 1 h-1), and metabolites derived from the S-isomer represented 80-90% of the urinary recovery of the dose. 4. Over 85 days, 4.4 +/- 2.9 and 3.3 +/- 1.8% of the dose was recovered in urine as unchanged S(+)-HCQ and R(-)-HCQ, respectively. For the first 2 weeks, S(+)-HCQ excretion rate clearly surpassed that of R(-)-HCQ whereas afterwards the inverse was observed. However, since the first 2 weeks account for 95% of rac-HCQ renal excretion, the total urinary excretion of S(+)-HCQ clearly surpassed that of R(-)-HCQ.(ABSTRACT TRUNCATED AT 250 WORDS)